Hepatic steatosis as diabetes type 2 predictor;Esteatosis Hepática: ¿Preludio de diabetes tipo 2 en población pediátrica?

Nutricion Hospitalaria

Volumn 29, Issue 2, 2014, Pages 350-358

  Loureiro, Carolina ^a   Martínez Aguayo, Alejandro ^a   Campino, Carmen ^a   Carvajal, Cristián ^a   Fardella, Carlos ^a   García, Hernán ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

Alanine aminotransferase; Insulin resistance; Non alcoholic fatty liver disease (NAFLD); Steatohepatitis; Type 2 diabetes

Indexed keywords

ALANINE AMINOTRANSFERASE; BIOLOGICAL MARKER;

ADOLESCENT; BLOOD; CHILD; COMPLICATION; DIABETES MELLITUS, TYPE 2; FEMALE; HUMAN; INSULIN RESISTANCE; MALE; NON-ALCOHOLIC FATTY LIVER DISEASE; PRESCHOOL CHILD;

ADOLESCENT; ALANINE TRANSAMINASE; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INSULIN RESISTANCE; MALE; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 84896815062     PISSN: 02121611     EISSN: 16995198     Source Type: Journal    
DOI: 10.3305/nh.2014.29.2.7098     Document Type: Article

References (43)

1. Brunt EM. Pathology of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2010; 7 (4): 195-203.
2. Nobili V, Alkhouri N, Bartuli A, Manco M, Lopez R, Alisi A y cols. Severity of liver injury and atherogenic lipid profile in children with nonalcoholic fatty liver disease. Pediatr Res 2010; 67 (6): 665-70.
3. l'Allemand-Jander D. Clinical diagnosis of metabolic and cardiovascular risks in overweight children: early development of chronic diseases in the obese child. Int J Obes (Lond) 2010; 34 (Suppl. 2): S32-6.
4. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P y cols. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123 (1): 134-40.
5. Alisi A, Manco M, Vania A, Nobili V. Pediatric nonalcoholic fatty liver disease in 2009. J Pediatr 2009; 155 (4): 469-74.
6. Shannon A, Alkhouri N, Carter-Kent C, Monti L, Devito R, Lopez R y cols. Ultrasonographic quantitative estimation of hepatic steatosis in children With NAFLD. J Pediatr Gastroenterol Nutr 2011; 53 (2): 190-5.
7. Barlow SE. Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report. Pediatrics 2007; 120 (Suppl. 4): S164-92.
8. Fagot-Campagna A, Pettitt DJ, Engelgau MM, Burrows NR, Geiss LS, Valdez R y cols. Type 2 diabetes among North American children and adolescents: an epidemiologic review and a public health perspective. J Pediatr 2000; 136 (5): 664-72.
9. D'Adamo E, Caprio S. Type 2 diabetes in youth: epidemiology and pathophysiology. Diabetes Care 2011; 34 (Suppl. 2): S161-5.
10. Cali AM, De Oliveira AM, Kim H, Chen S, Reyes-Mugica M, Escalera S y cols. Glucose dysregulation and hepatic steatosis in obese adolescents: is there a link? Hepatology 2009; 49 (6): 1896-903.
11. Schwimmer JB, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C. Prevalence of fatty liver in children and adolescents. Pediatrics 2006; 118 (4): 1388-93.
12. Kim JS, Le KA, Mahurkar S, Davis JN, Goran MI. Influence of elevated liver fat on circulating adipocytokines and insulin resistance in obese Hispanic adolescents. Pediatr Obes 2012; 7 (2): 158-64.
13. Scherer PE. Adipose tissue: from lipid storage compartment to endocrine organ. Diabetes 2006; 55 (6): 1537-45.
14. Maury E, Brichard SM. Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol Cell Endocrinol 2010; 314 (1): 1-16.
15. Eyzaguirre F, Silva R, Roman R, Palacio A, Cosentino M, Vega V y cols. Prevalence of metabolic syndrome in children and adolescents who consult with obesity. Rev Med Chil 2011; 139 (6): 732-8.
16. Falkner B, Daniels SR. Summary of the Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents. Hypertension 2004; 44 (4): 387-8.
17. Martinez-Aguayo A, Aglony M, Campino C, Garcia H, Bancalari R, Bolte L y cols. Aldosterone, plasma Renin activity, and aldosterone/renin ratio in a normotensive healthy pediatric population. Hypertension 2010; 56 (3): 391-6.
18. Conwell LS, Trost SG, Brown WJ, Batch JA. Indexes of insulin resistance and secretion in obese children and adolescents: a validation study. Diabetes Care 2004; 27 (2): 314-9.
19. Fraser A, Harris R, Sattar N, Ebrahim S, Davey Smith G, Lawlor DA. Alanine aminotransferase, gamma-glutamyltransferase, and incident diabetes: the British Women's Heart and Health Study and meta-analysis. Diabetes Care 2009; 32 (4): 741-50.
20. Stein LL, Dong MH, Loomba R. Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status. Adv Ther 2009; 26 (10): 893-907.
21. Cheung O, Kapoor A, Puri P, Sistrun S, Luketic VA, Sargeant CC y cols. The impact of fat distribution on the severity of nonalcoholic fatty liver disease and metabolic syndrome. Hepatology 2007; 46 (4): 1091-100.
22. Kursawe R, Eszlinger M, Narayan D, Liu T, Bazuine M, Cali AM y cols. Cellularity and adipogenic profile of the abdominal subcutaneous adipose tissue from obese adolescents: association with insulin resistance and hepatic steatosis. Diabetes 2010; 59 (9): 2288-96.
23. Bosy-Westphal A, Booke CA, Blocker T, Kossel E, Goele K, Later W y cols. Measurement site for waist circumference affects its accuracy as an index of visceral and abdominal subcutaneous fat in a Caucasian population. J Nutr 2010; 140 (5): 954-61.
24. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010; 51 (5): 1820-32.
25. Seppala-Lindroos A, Vehkavaara S, Hakkinen AM, Goto T, Westerbacka J, Sovijarvi A y cols. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 2002; 87 (7): 3023-8.
26. Qi NR, Wang J, Zidek V, Landa V, Mlejnek P, Kazdova L y cols. A new transgenic rat model of hepatic steatosis and the metabolic syndrome. Hypertension 2005; 45 (5): 1004-11.
27. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004; 114 (2): 147-52.
28. Chen SH, He F, Zhou HL, Wu HR, Xia C, Li YM. Relationship between nonalcoholic fatty liver disease and metabolic syndrome. J Dig Dis 2011; 12 (2): 125-30.
29. Manco M, Bottazzo G, DeVito R, Marcellini M, Mingrone G, Nobili V. Nonalcoholic fatty liver disease in children. J Am Coll Nutr 2008; 27 (6): 667-76.
30. Fraser A, Longnecker MP, Lawlor DA. Prevalence of elevated alanine aminotransferase among US adolescents and associated factors: NHANES 1999-2004. Gastroenterology 2007; 133 (6): 1814-20.
31. Sartorio A, Del Col A, Agosti F, Mazzilli G, Bellentani S, Tiribelli C y cols. Predictors of non-alcoholic fatty liver disease in obese children. Eur J Clin Nutr 2007; 61 (7): 877-83.
32. Braunersreuther V, Viviani GL, Mach F, Montecucco F. Role of cytokines and chemokines in non-alcoholic fatty liver disease. World J Gastroenterol 2012; 18 (8): 727-35.
33. Louthan MV, Barve S, McClain CJ, Joshi-Barve S. Decreased serum adiponectin: an early event in pediatric nonalcoholic fatty liver disease. J Pediatr 2005; 147 (6): 835-8.
34. Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 2000; 343 (20): 1467-76.
35. Montecucco F, Mach F. Does non-alcoholic fatty liver disease (NAFLD) increase cardiovascular risk? Endocr Metab Immune Disord Drug Targets 2008; 8 (4): 301-7.
36. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesitylinked insulin resistance. Science 1993; 259 (5091): 87-91.
37. Kishimoto T. IL-6: from its discovery to clinical applications. Int Immunol 2010; 22 (5): 347-52.
38. El-Assal O, Hong F, Kim WH, Radaeva S, Gao B. IL-6-deficient mice are susceptible to ethanol-induced hepatic steatosis: IL-6 protects against ethanol-induced oxidative stress and mitochondrial permeability transition in the liver. Cell Mol Immunol 2004; 1 (3): 205-11.
39. Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 2000; 148 (2): 209-14.
40. Klover PJ, Clementi AH, Mooney RA. Interleukin-6 depletion selectively improves hepatic insulin action in obesity. Endocrinology 2005; 146 (8): 3417-27.
41. Lebensztejn DM, Wojtkowska M, Skiba E, Werpachowska I, Tobolczyk J, Kaczmarski M. Serum concentration of adiponectin, leptin and resistin in obese children with non-alcoholic fatty liver disease. Adv Med Sci 2009; 54 (2): 177-82.
42. Musso G, Gambino R, Durazzo M, Biroli G, Carello M, Faga E y cols. Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease. Hepatology 2005; 42 (5): 1175-83.
43. Venturi C, Zoppini G, Zamboni C, Muggeo M. Insulin sensitivity and hepatic steatosis in obese subjects with normal glucose tolerance. Nutr Metab Cardiovasc Dis 2004; 14 (4): 200-4